Highlights Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-13 EDT			5-day change	1st Jan Change
31.34 ^USD	-0.25%		+5.06%	+1.75%

08-12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
08-12	Nordic stocks in North America: AstraZeneca fell 1.0%	FW

Highlights

08-07	Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course
08-07	Genmab soars after raising its guidance
08-06	Genmab A/S Revises Earnings Guidance for the Year 2026	CI
08-06	Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Genmab Lifts FY26 Earnings Guidance	MT
07-23	Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma	CI
07-06	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination	MT
07-06	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
06-29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
06-24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
06-23	Genmab: Financing weighs now, pipeline pays later
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
05-11	Genmab Rebounds on UBS Support
05-07	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Genmab Q1 Net Profit Falls, Revenue Rises	MT
05-07	Genmab reports Q1 operating profit of $180 million	RE
05-07	Genmab A/S maintains Financial Guidance for 2026	CI
05-06	Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 31, 2025.	CI
04-14	Genmab Posts Higher Darzalex Net Sales in Q1	MT
04-14	Genmab Q1 Darzalex net sales at $3,964 mln	RE
04-13	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
04-08	Jefferies Stays Optimistic on Genmab
03-16	Genmab Wraps Up Share Repurchase Program	MT
03-16	Genmab completed share buy-back program on March 13	RE